About: Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety
Creator	Jeevaratnam, Kamalan Takla, Michael
source	MedRxiv
abstract	Background: The COVID-19 pandemic has required clinicians to urgently identify new treatment options or the repurposing of existing drugs. Several drugs are now being repurposed with the aim of identifying if these drugs provide some level of disease resolution. Of particular interest are chloroquine (CQ) and hydroxychloroquine (HCQ), first developed as an antimalarial therapy. There is increasing concern with regards to the efficacy and safety of these agents. The aims of this review are to systematically identify and collate studies describing the use of CQ and HCQ in human clinical trials and provide a detailed synthesis of evidence of its efficacy and safety. Methods and Findings: Searches for (COVID AND chloroquine [title/abstract] AND outcomes[full text]) and two (COVID AND hydroxychloroquine[title/abstract] AND outcomes[full text]) yielded 272 unique articles. Unique articles were manually checked for inclusion and exclusion criteria and also subjected to a quality appraisal assessment. A total of 19 articles were included in the systematic review. Seventy-five percent of observational studies employing an endpoint specific to efficacy recorded no significant difference in the attainment of outcomes, between COVID-19 patients given a range of CQ and/or HCQ doses, and the control groups. All clinical trials and 82% of observational studies examining an indicator unique to drug safety discovered a higher probability of adverse events in those treated patients suspected of, and diagnosed with, COVID-19. Seventy-five percent of the total papers focusing on cardiac side-effects found a greater incidence among patients administered a wide range of CQ and/or HCQ doses, with QTc prolongation the most common finding, in addition to its consequences of VT and cardiac arrest. Of the total studies using mortality rate as an end-point, 60% reported no significant change in the risk of death, while 30% showed an elevation, and 10% a depression, in treated relative to control patients. Conclusion: The strongest available evidence suggests that, relative to standard in-hospital management of symptoms, the use of CQ and HCQ to treat hospitalised COVID-19 patients has likely been unsafe. At the very least, the poor quality of data failing to find any significant changes in the risk of VT should preclude definitive judgment on drug safety until the completion of high-quality randomised clinical trials.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1101/2020.05.28.20115741
has license	medrxiv
sha1sum (hex)	6d7cbd0ad69a49f59dfe4a1e6495d5db55171825
schema:url	https://doi.org/10.1101/2020.05.28.20115741
resource representing a document's title	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety
resource representing a document's body	covid:6d7cbd0ad69a49f59dfe4a1e6495d5db55171825#body_text
is schema:about of	named entity 'therapy' named entity 'Systematic review' named entity 'disease' named entity 'Background' named entity 'safety' named entity 'studies' named entity 'narrative' named entity 'chloroquine' named entity 'HCQ' named entity 'hydroxychloroquine' named entity 'controlled trials' named entity 'COVID' named entity 'COVID' named entity 'QTc prolongation' named entity 'statistical evidence' named entity 'COVID' named entity 'RNA' named entity 'WHO' named entity 'placebo' named entity 'peer-reviewed' named entity 'CC-BY-NC-ND 4.0' named entity 'PICOT' named entity 'VTs' named entity 'HCQ' named entity 'HCQ' named entity 'COVID-19' named entity 'risk of death' named entity 'EndNote' named entity 'COVID' named entity 'observational studies' named entity 'COVID' named entity 'medRxiv' named entity 'control group' named entity 'control groups' named entity 'CC-BY-NC-ND 4.0' named entity 'clinical trials' named entity 'observational studies' named entity 'proteolytic cleavage' named entity 'Western Medicine' named entity 'CC-BY-NC-ND 4.0' named entity 'CC-BY-NC-ND 4.0' named entity 'COVID-19' named entity 'cytokine storm' named entity 'COVID' named entity 'HCQ' named entity 'COVID-19' named entity 'HCQ' named entity 'lopinavir/ritonavir' named entity 'systematic review' named entity 'clinical trial' named entity 'ICU' named entity 'CC-BY-NC-ND 4.0' named entity 'SARS' named entity 'HCQ' named entity 'COVID-19' named entity 'selection bias' named entity 'antibiotics' named entity 'clinical trials' named entity 'nausea' named entity 'adverse effects' named entity 'clinical data' named entity 'macrolide antibiotic' named entity 'clinical setting' named entity 'symptom' named entity 'CC-BY-NC-ND 4.0' named entity 'significant difference' named entity 'data quality' named entity 'respiratory failure' named entity 'azithromycin' named entity 'CXR' named entity 'systematic review' named entity 'QT prolongation' named entity 'mortality rate' named entity 'placebo' named entity 'TLR7' named entity 'antigen presentation' named entity 'torsades de pointe' named entity 'Wuhan' named entity 'TMPRSS2' named entity 'abortion' named entity 'treatment group' named entity 'Systematic Reviews' named entity 'control group' named entity 'lopinavir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software